I am far from a short you old cogger. I am not a spry guy
I am far from a short you old cogger. I am not a spry guy myself. You can call me short if you feel that helps your argument with that 3rd rate cancer therapy. lol... I also have to say I feel that all drugs if they provide relief or help in any way have value. Maybe Trodelvy has value? Maybe it gets used after everything is exhausted? Maybe new information is released that gives it a better chance as a first use drug. I am happy for your investment and the rise you will see tomorrow when the news of Gilead buyout hits the stock price. GLTU.
My main point was market share and use and I believe Leronlimab should have the market share when it happens to get approved with that excellent safety record and mechanism of action that reduces CTC to zero and maintains that zero CTC. I hope and would like believe it will bridge the gap for a partial cure by stopping all future metastasis. Hopefully when used with other cancer treatments it might just be combined into a cure for all the solid tumor cancers. That remains to be seen but just think if we could be a part of curing some of the nastiest deadly cancers out there.
All I can say to you is that Leronlimab is going to be an Achilles heel for many Big Pharma companies if everything we know to be true actually holds to be true. I believe in our CEO Nader and have never said a cross word about Nader or the CYDY management team.
By the way, I have a 5 figure amount of stock and average $.34/share. Had my one year anniversary of ownership last month. I consider myself long and I have never sold a share of CYDY since my original purchase. Why you might ask. It’s because I believe in Leronlimab and it’s mechanism of action not just working for one indication but many anti inflammatory mechanisms of action and immune modulations and so likely working for many diseases. I am all in because I believe. Hoping for a great next 30 days! With two approvals and an uplisting and a cancer BTD filed. Not necessarily in any specific order. I will take all 4 in any order they come. Good luck to us all...
5
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Game Changer for Surrogacy Agencies When we talk about innovation, we often focus on the flashiest tech in finance or the buzz of a scorching hot stock. But here's Ouma Health, shifting gears in a sector many traders don't blink at—surrogacy. They're unveiling Ouma Connect, a portal pulling back the curtain on medical clearances for gestational-carrier candidates....
Continue Reading
Record-Breaking Quarter Amid Challenging Times When Mission Bancorp's earnings hit the tape today, the numbers were enough to catch anyone's eye—$9.2 million in net income for Q3 2026, a 6% increase from last year. That's not small potatoes, especially considering the economic fog we're navigating through. AJ Antongiovanni, holding the reins as CEO, credits the bank's...
Continue Reading
Ernesta's Southeast Play: The Atlanta Showroom Here's something to turn heads in the world of custom home design—Ernesta has just set up shop in Atlanta, a move that speaks volumes about their ambitions in the Southeast market. This isn't just about selling a few more rugs; it's a calculated step into a region ripe with design potential and a hunger for bespoke home...
Continue Reading
A Glance at SoftwareOne's Unyielding Dominance Call it a streak, call it consistency—either way, SoftwareOne's nailed it yet again, bagging the Leader spot in Gartner's Magic Quadrant for SAM Managed Services for the seventh straight year. Yep, seven years running. This ain't just a piece of paper to hang on the office wall. It's a testament to their grit in helping...
Continue Reading
Another Day, Another Lawsuit Just when you thought the financial waters were calm, there's a storm brewing for Bank of America Corp. (NYSE: BAC). They've been slapped with a securities class action lawsuit that screams all kinds of regulatory and compliance failures. You’d think with all that cash flow, BAC could afford to run a tight ship. But apparently, they decided...
Continue Reading
Fulcra Dynamics Pushes the Boundaries with New Tool There's always that moment when a company nudges the needle, and Fulcra Dynamics seems to have done just that with its latest release. They've unveiled an ingenious tool that promises a shake-up in how we build and use web applications with AI. It's the kind of move that makes you stop and wonder if we're witnessing the...
Continue Reading
Retirement Industry Shake-Up Here's the scoop: Mesirow's swinging big in the retirement scene with its latest acquisition of flexPATH's plan-level 3(38) business. In the world of outsourced fiduciarity—for thems ain't in the know—that's like bolting a turbocharger to an already darn good engine. Mesirow might just be strapping itself in for a wild ride in this 2026...
Continue Reading
Better Home & Finance Navigates Turbulent Waters Not every day the news comes up smelling of roses, and that's putting it lightly for Better Home & Finance, trading as NASDAQ: BETR. When you're talking about a splash that sends shockwaves, losing over 28% of your stock value on a single trading day is one whale of a splash indeed. The Numbers That Shook the Waters It's no...
Continue Reading
Dalrymple's Short Report Shakes Csquare's Core Csquare, Inc. (NYSE: CSQR) is reeling from a one-two punch: a damning short report by Dalrymple Finance and an 11.8% share tumble. The timing of this financial body blow, coinciding with Csquare's discordant cash flow claims, could mark the beginning of a long battle for investor trust. This ain't the first time the markets...
Continue Reading
Shifting the Landscape of Private Tutoring Here's a turn of events: parents now have a new tool at their disposal to vet private tutors. The recently unveiled PGCE Tutoring by UWE Bristol aims to provide an added layer of confidence for families navigating the private tutoring market. Breaking the Myth of Tutor Qualifications Did you know a whopping 54% of UK adults think...
Continue Reading
Top 5 Most Recently Viewed Articles
Pennybacker Capital Expands Leadership Team with Key Appointment Pennybacker Capital Management, LLC, a leading investment manager specializing in real assets, has made an important addition to its leadership team. The firm has appointed Carey Doyle as the new Managing Director of Capital Formation. This move is part of Pennybacker's ongoing effort to strengthen its...
Continue Reading
Batteries Plus Expands Franchise Operations in Thriving Hub Batteries Plus, a leading specialty battery franchise, has recently signed an exciting multi-unit franchise agreement to open four new stores in a vibrant economic center. The franchise aims to serve the local community by providing reliable power solutions that cater to the needs of various sectors, including...
Continue Reading
U.S. Appeals Court Decisions and Tariff Implications A significant ruling emerged from a U.S. appeals court, declaring that many tariffs imposed by President Donald Trump are unconstitutional. This decision came as a surprise to many and has sparked a wave of reactions, especially from the ex-president, who labeled it as 'highly partisan'. Economists and political...
Continue Reading
Important Update for Neumora Therapeutics Investors For investors holding stock in Neumora Therapeutics, Inc. (NASDAQ: NMRA), there's a significant class action lawsuit in progress that you need to be aware of. This is a crucial time for all shareholders to take proactive steps as the deadline for becoming a lead plaintiff approaches. Class Action Lawsuit Details The...
Continue Reading
TeraBox's Commitment to Online Safety TeraBox, a globally trusted cloud storage service, has recently published its third-quarter transparency report, outlining the steps taken to combat illegal content dissemination online. The report illustrates the company's unwavering dedication to creating a secure online environment for its users. Significant Findings in the Latest...
Continue Reading